Corrections: Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study (The Lancet Neurology (2018) 17(4) (335–346)(S1474442218300292)(10.1016/S1474-4422(18)30029-2));Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study

The Lancet Neurology

Volumn 17, Issue 4, 2018, Pages 335-346

  Dubois, Bruno ^a   Epelbaum, Stephane ^a   Nyasse, Francis ^a   Bakardjian, Hovagim ^a   Gagliardi, Geoffroy ^a   Uspenskaya, Olga ^b   Houot, Marion ^a   Lista, Simone ^a   Cacciamani, Federica ^a   Potier, Marie Claude ^a   Bertrand, Anne ^a   Lamari, Foudil ^a   Benali, Habib ^a   Mangin, Jean François ^c   Colliot, Olivier ^a   Genthon, Remy ^a   Habert, Marie Odile ^a   Hampel, Harald ^a   Audrain, Christelle ^d   Auffret, Alexandra ^d   Baldacci, Filippo ^d   Benakki, Ismahane ^d   Bertin, Hugo ^d   Boukadida, Laurie ^d   Cavedo, Enrica ^d   Chiesa, Patrizia ^d   Dauphinot, Luce ^d   Dos Santos, Antonio ^d   Dubois, Marion ^d   Durrleman, Stanley ^d   Fontaine, Gaëlle ^d   Genin, Alexis ^d   Glasman, Pauline ^d   Jungalee, Navichka ^d   Kas, Aurélie ^d   Kilani, Maya ^d   La Corte, Valentina ^d   Lehericy, Stephane ^d   Letondor, Claire ^d   Levy, Marcel ^d   Lowrey, Mark ^d   Ly, Juliette ^d   Makiese, Ornella ^d   Metzinger, Christiane ^d   Michon, Agnès ^d   Mochel, Fanny ^d   Poisson, Catherine ^d   Ratovohery, Stephie ^d   Revillon, Marie ^d   Rojkova, Katrine ^d   Roy, Perrine ^d   Santos Andrade, Katia ^d   Schindler, Rachel ^d   Seux, Laure ^d   Simon, Valérie ^d   Sole, Marine ^d   Tandetnik, Caroline ^d   Teichmann, Marc ^d   Thiebaut de Shotten, Michel ^d   Younsi, Nadjia ^d   more..

^a SORBONNE UNIVERSITÉ   (France)

^b IQVIA   (United States)

^c DIF   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; TAU PROTEIN; THREONINE; THREONINE 181; UNCLASSIFIED DRUG;

ACTIMETRY; AGED; ALLELE; ALZHEIMER DISEASE; AMYLOIDOSIS; ANTERIOR CINGULATE; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR; BEHAVIOR ASSESSMENT; BRAIN; BRAIN METABOLISM; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL DEMENTIA RATING; COGNITION; COGNITION ASSESSMENT; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTROENCEPHALOGRAM; EMOTION; EPISODIC MEMORY; FEMALE; FOLLOW UP; FREE AND CUED SELECTIVE REMINDING TEST; FUNCTIONAL NEUROIMAGING; GLUCOSE METABOLISM; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; MOOD; NEUROIMAGING; NEUROLOGIC DISEASE ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PARS ORBITALIS; PERSONAL AUTONOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; QUALITY OF LIFE; RIGHT HIPPOCAMPUS; TRAIL MAKING TEST; DIAGNOSTIC IMAGING; METABOLISM; NEUROPSYCHOLOGICAL TEST; PATHOLOGY; PHYSIOLOGY; PSYCHOLOGY; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BRAIN; COGNITION; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; NEUROIMAGING; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RISK FACTORS;

EID: 85042644236     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(18)30153-4     Document Type: Erratum

References (60)

1. Dubois, B, Feldman, HH, Jacova, C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6 (2007), 734–746.
2. Dubois, B, Feldman, HH, Jacova, C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9 (2010), 1118–1127.
3. Sperling, RA, Aisen, PS, Beckett, LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
4. Albert, MS, DeKosky, ST, Dickson, D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
5. McKhann, GM, Knopman, DS, Chertkow, H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 263–269.
6. Dubois, B, Hampel, H, Feldman, HH, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12 (2016), 292–323.
7. Clark, LR, Racine, AM, Koscik, RL, et al. Beta-amyloid and cognitive decline in late middle age: findings from the Wisconsin Registry for Alzheimer's Prevention study. Alzheimers Dement 2 (2016), 805–814.
8. Donohue, MC, Sperling, RA, Salmon, DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol 71 (2014), 961–970.
9. Langbaum JB, Hendrix SD, Ayutyanont N, et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement 10: 666–74.
10. Lim, YY, Maruff, P, Pietrzak, RH, et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 137 (2014), 221–231.
11. Lim, YY, Snyder, PJ, Pietrzak, RH, et al. Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: introducing the Z-scores of attention, verbal fluency, and episodic memory for nondemented older adults composite score. Alzheimers Dement (Amst) 2 (2015), 19–26.
12. Mormino, EC, Papp, KV, Rentz, DM, et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid-β. Alzheimers Dement 13 (2017), 1004–1012.
13. Folstein, MF, Folstein, SE, McHugh, PR, “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975), 189–198.
14. Morris, JC, The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993), 2412–2414.
15. Buckley, R, Saling, MM, Ames, D, et al. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. Int Psychogeriatr 25 (2013), 1307–1315.
16. McNair, M, Kahn, R, Self-assessment of cognitive deficits. Crook, T, Ferris, S, Bartus, (eds.) Assessment in geriatric psychopharmacology, 1983, Mark Powley Associates, New Canaan, CT, 137–144.
17. Monahan, PO, Boustani, MA, Alder, C, et al. Practical clinical tool to monitor dementia symptoms: the HABC-Monitor. Clin Interv Aging 7 (2012), 143–157.
18. Cacciamani, F, Tandetnik, C, Gagliardi, G, et al. Low cognitive awareness, but not complaint, is a good marker of preclinical Alzheimer's disease. J Alzheimers Dis 59 (2017), 753–762.
19. Cummings, JL, Mega, M, Gray, K, Rosenberg-Thompson, S, Carusi, DA, Gornbein, J, The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44 (1994), 2308–2314.
20. Spielberger, CD, Gorsuch, RL, Lushene, R, Vagg, PR, Jacobs, GA, Manual for the State-Trait Anxiety Inventory. 1983, Consulting Psychologists Press, Palo Alto, CA.
21. Yesavage, JA, Brink, TL, Rose, TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17 (1982–1983), 37–49.
22. Starkstein, SE, Migliorelli, R, Manes, F, et al. The prevalence and clinical correlates of apathy and irritability in Alzheimer's disease. Eur J Neurol 2 (1995), 540–546.
23. Bucks, RS, Ashworth, DL, Wilcock, GK, Siegfried, K, Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 25 (1996), 113–120.
24. Sikkes, SA, de Lange-de Klerk, ES, Pijnenburg, YA, et al. A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement 8 (2012), 536–543.
25. Brooks, R, EuroQoL: the current state of play. Health Policy 37 (1996), 53–72.
26. Barbeau, E, Didic, M, Tramoni, E, et al. Evaluation of visual recognition memory in MCI patients. Neurology 62 (2004), 1317–1322.
27. Osterrieth, PA, Le test de copie d'une figure complexe: contribution à l'étude de la perception et de la mémoire. Arch Psychol 30 (1944), 206–356.
28. Buschke, H, Mowrey, WB, Ramratan, WS, et al. Memory Binding Test distinguishes amnestic mild cognitive impairment and dementia from cognitively normal elderly. Arch Clin Neuropsychol 32 (2017), 29–39.
29. Wechsler, D, Wechsler Memory Scale. 1975, Psychological Corporation, New-York, NY.
30. Dubois, B, Slachevsky, A, Litvan, I, Pillon, B, The FAB: a Frontal Assessment Battery at bedside. Neurology 55 (2000), 1621–1626.
31. Tombaugh, TN, Trail Making Test A and B: normative data stratified by age and education. Arch Clin Neuropsychol 19 (2004), 203–214.
32. Thurstone, LL, Psychophysical analysis. By L L Thurstone, 1927. Am J Psychol 100 (1987), 587–609.
33. Deloche, G, Hannequin, D, Dordain, M, et al. Picture confrontation oral naming: performance differences between aphasics and normals. Brain Lang 53 (1996), 105–120.
34. Peigneux, P, Van der Liden, M, Presentation d'une batterie neuropsychologique et cognitive pour l'evaluation de l'apraxie gestuelle. Rev Neuropsychol 10 (2000), 311–362.
35. Clark, CM, Schneider, JA, Bedell, BJ, et al. Use of florbetapir-PET for imaging β-amyloid pathology. JAMA 305 (2011), 275–283.
36. Besson, FL, La Joie, R, Doeuvre, L, et al. Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer's disease. J Neurosci 35 (2015), 10402–10411.
37. La Joie, R, Perrotin, A, Barré L, et al. Region-specific hierarchy between atrophy, hypometabolism, and β-amyloid (aβ) load in Alzheimer's disease dementia. J Neurosci 32 (2012), 16265–16273.
38. Landau, SM, Thomas, BA, Thurfjell, L, et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 41 (2014), 1398–1407.
39. Jack, CR Jr, Knopman, DS, Weigand, SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 71 (2012), 765–775.
40. Chupin, M, Hammers, A, Liu, RS, et al. Automatic segmentation of the hippocampus and the amygdala driven by hybrid constraints: method and validation. Neuroimage 46 (2009), 749–761.
41. Blennow, K, Hampel, H, Weiner, M, Zetterberg, H, Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6 (2010), 131–144.
42. Epelbaum, S, Genthon, R, Cavedo, E, et al. Preclinical Alzheimer's disease: a systematic review of the cohorts underlying the concept. Alzheimers Dement 13 (2017), 454–467.
43. Dubois, B, Feldman, HH, Jacova, C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
44. Simel, DL, Samsa, GP, Matchar, DB, Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 44 (1991), 763–770.
45. Rowe, C, Ames, D, Ellis, K, et al. Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL). Alzheimer Dement, 9(suppl), 2013, 12 (abstr IC-P-004).
46. Jansen, WJ, Ossenkoppele, R, Knol, DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA 313 (2015), 1924–1938.
47. Duyckaerts, C, Tau pathology in children and young adults: can you still be unconditionally baptist?. Acta Neuropathol 121 (2011), 145–147.
48. Villemagne, VL, Pike, KE, Chételat, G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol 69 (2011), 181–192.
49. Vos, SJ, Xiong, C, Visser, PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 12 (2013), 957–965.
50. Soldan, A, Pettigrew, C, Cai, Q, et al. Hypothetical preclinical Alzheimer disease groups and longitudinal cognitive change. JAMA Neurol 73 (2016), 698–705.
51. Fortea, J, Vilaplana, E, Alcolea, D, et al. Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Ann Neurol 76 (2014), 223–230.
52. Papp, KV, Amariglio, RE, Mormino, EC, et al. Free and cued memory in relation to biomarker-defined abnormalities in clinically normal older adults and those at risk for Alzheimer's disease. Neuropsychologia 73 (2015), 169–175.
53. Amariglio, RE, Becker, JA, Carmasin, J, et al. Subjective cognitive complaints and amyloid burden in cognitively normal older individuals. Neuropsychologia 50 (2012), 2880–2886.
54. Tisserand, DJ, Jolles, J, On the involvement of prefrontal networks in cognitive ageing. Cortex 39 (2003), 1107–1128.
55. Du, AT, Schuff, N, Chao, LL, et al. Age effects on atrophy rates of entorhinal cortex and hippocampus. Neurobiol Aging 27 (2006), 733–740.
56. Buckley, R, Saling, MM, Ames, D, et al. Factors affecting subjective memory complaints in the AIBL aging study: biomarkers, memory, affect, and age. Int Psychogeriatr 25 (2013), 1307–1315.
57. Hollands, S, Lim, YY, Buckley, R, et al. Amyloid-β related memory decline is not associated with subjective or informant rated cognitive impairment in healthy adults. J Alzheimers Dis 43 (2015), 677–686.
58. Jessen, F, Amariglio, RE, van Boxtel, M, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 10 (2014), 844–852.
59. Turner, GR, Spreng, RN, Prefrontal engagement and reduced default network suppression co-occur and are dynamically coupled in older adults: the default-executive coupling hypothesis of aging. J Cogn Neurosci 27 (2015), 2462–2476.
60. Jack, CR Jr, Wiste, HJ, Weigand, SD, Therneau, TM, et al. Age-specific and sex-specific prevalence of cerebral β-amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50–95 years: a cross-sectional study. Lancet Neurol 16 (2017), 435–444.